Home | Events | Going Global – How can funding support my international goals for my Life Sciences business

Going Global – How can funding support my international goals for my Life Sciences business

20 June 2023
Member events

This webinar is the second in a series of three from Freeths & MHA

20 June 2023
16:00 – 17:00
Online webinar
View the map

In association with Freeths & MHA, this webinar, the second in a series of three, aims to tackle a number of connected topics critical to commercial success: understanding the kinds of funding you need to take your business to the next level and how to access it, as well as the legal considerations during the raising of finance.

The webinar will look to cover: 

  • Overall trends in the capital markets environment for life sciences companies globally and in Europe in particular
  • The various funding options available to life sciences companies 
  • Legal considerations from an investor and investee point during a fund raise. 


Yogan A. Patel
Partner and Life Sciences Industry Lead at MHA

Yogan will lead the panel discussion, he heads up the Pharma, Life Science and Med-Tech sector for MHA.

Rob Dando

Corporate Finance Partner and Transaction Services Leader

Rob leads the Corporate Finance, Transaction Services team at MHA. Rob has over 15 years’ transaction consultancy experience, with considerable knowledge in global markets. He specialises in advising mid-market businesses, corporate clients and financial institutions, in their assessment of acquisitions and divestments, as well as assisting organisations on their journey to initial public offering. Rob’s primary focus is on providing financial due diligence services for M&A transactions. Rob has extensive deal experience across a variety of industry sectors, deal sizes and on a global basis.

Karolina Zapadka
Investment Manager at Parkwalk Advisors

Karolina has over a decade of experience building life sciences and healthcare companies within the Cambridge Cluster. Karolina played a pivotal role in securing pre-seed, seed, and Series A investments from a stellar syndicate of investors. In 2018 she co-founded and successfully delivered the first life sciences startup accelerator in Cambridge with a portfolio value of over £90m. She started her career as a scientist at a leading biopharmaceutical company delivering a portfolio of products to clinics. Karolina completed a PhD in protein folding/metabolic science from the University of Cambridge and carried out a drug development postdoc work at MedImmune/AstraZeneca. 

Claus Andersen
Partner, Life Sciences, Freeths 

Claus specialises in all aspects of corporate and commercial work with a particular focus on mergers and acquisitions, shareholder agreements, joint ventures, licencing agreements and regulatory advice to companies and businesses in the Life Sciences and technology sector. Claus has also a wealth of experience in relation to inward investment, ie. overseas companies investing into the UK. Claus has for more than 15 years advised a number of businesses from Scandinavia, Central and Western Europe, Asia and the US about investing in the UK and what such businesses should look out for in that process.